Burning Rock Biotech (BNR) vs. Its Competitors Financial Review

Burning Rock Biotech (NASDAQ:BNR) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Burning Rock Biotech to similar companies based on the strength of its institutional ownership, risk, valuation, earnings, dividends, analyst recommendations and profitability.

Valuation & Earnings

This table compares Burning Rock Biotech and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Burning Rock Biotech	$77.16 million	-$7.92 million	-15.32
Burning Rock Biotech Competitors	$700.54 million	$9.44 million	-18.96

Burning Rock Biotech’s rivals have higher revenue and earnings than Burning Rock Biotech. Burning Rock Biotech is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Burning Rock Biotech has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Burning Rock Biotech’s rivals have a beta of -1.84, meaning that their average stock price is 284% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Burning Rock Biotech and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1	0	0	0	1.00
Burning Rock Biotech Competitors	9869	15284	45614	1598	2.54

As a group, “Biotechnology” companies have a potential upside of 124.57%. Given Burning Rock Biotech’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Burning Rock Biotech has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Burning Rock Biotech and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-13.60%	-12.98%	-8.59%
Burning Rock Biotech Competitors	-12,323.33%	-195.91%	-30.60%

Summary

Burning Rock Biotech rivals beat Burning Rock Biotech on 7 of the 13 factors compared.

About Burning Rock Biotech

Burning Rock Biotech Limited is a biotechnology company focused on precision oncology. The company develops and commercializes next-generation sequencing (NGS) tests designed to help detect cancer, guide treatment decisions and monitor patients during therapy. Its offerings include tissue- and blood-based genomic testing for cancer patients, as well as tests intended to support therapy selection, treatment monitoring and the identification of biomarkers relevant to targeted medicines and immunotherapies.